Medical Condition News

RSS

Viatronix V3D-Colon software used for the President's colon cancer screening exam

Viatronix Incorporated, a Stony Brook, New York, based company announced that its V3D-Colon software is used at the National Naval Medical Center where the President's annual physical was done. "Our software is being utilized at several DOD facilities since the landmark Virtual Colonoscopy clinical trial published in the New England Journal of Medicine back in December 2003," said Zaffar Hayat, President of Viatronix Incorporated.

9 Mar 2010

Black and Hispanic Medicare beneficiaries with heart failure less likely to receive hospice care

Black and Hispanic Medicare beneficiaries with heart failure appear less likely to receive hospice care than white patients with the same condition, according to a report in the March 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

9 Mar 2010

Some anti-depressant drugs associated with increased chance of developing cataracts: Study

Some anti-depressant drugs are associated with an increased chance of developing cataracts, according to a new statistical study by researchers at the University of British Columbia, Vancouver Coastal Health Research Institute and McGill University.

9 Mar 2010

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

The Journal of the American Academy of Dermatology has published Phase III data evaluating the safety and efficacy of imiquimod cream at two doses – 2.5% and 3.75% – administered daily on either 2-week or 3-week treatment cycles.

9 Mar 2010

Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010.

9 Mar 2010

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.

9 Mar 2010

Well-characterized molecular alterations of sarcomas make them ideal models for developing new therapies

New breakthrough treatments for the most common cancers could soon come from cutting-edge research into some of the world's rarest tumors.

9 Mar 2010

Study suggests early warning signs for autism spectrum disorders within families

A new study suggests a trend toward developing hyperactivity among typically developing elementary-school-aged siblings of autistic preschoolers and supports the notion that mothers of young, autistic children experience more depression and stress than mothers with typically developing children.

9 Mar 2010

Weight and risk for diabetes decrease for people in communities where fast food prices increase: Study

A new study that followed participants for 20 years shows both weight and risk for diabetes decreased for people in communities where fast food prices increased.

9 Mar 2010

Obesity - Body's effort to protect organs from lipids' toxic effects

The collection of symptoms that is the metabolic syndrome-insulin resistance, high cholesterol, fatty liver, and a greater risk for diabetes, heart disease, and stroke-are all related to obesity, but, according to a review in the March 9th issue of the Cell Press publication Trends in Endocrinology and Metabolism, not in the way you probably think they are.

9 Mar 2010

Study finds sizeable position for Actemra in rheumatoid arthritis treatment paradigm

Results from a study conducted by Majestic Research suggest that Bristol Myers Squibb's Orencia, Johnson & Johnson's Remicade, and Amgen's/Wyeth's Enbrel will forfeit share of the rheumatoid arthritis market to Roche's newly launched Actemra. Early switching data from Majestic’s proprietary panel of rheumatologists indicates that Orencia may be the biggest loser of all, as 54% of switches to Actemra thus far have been from Orencia.

9 Mar 2010

New program specifically tailored to teens could help them manage and avoid asthma

An asthma program specifically tailored to teens could help those in rural areas manage their disease and avoid potentially fatal complications, Medical College of Georgia researchers say.

9 Mar 2010

RDS launches international outreach program on cognitive impairment in Down syndrome patients

Research Down Syndrome has launched an international outreach program to focus awareness and support for the rapidly advancing area of biomedical research leading to safe and effective approved medical therapies to treat cognitive impairment in individuals of all ages with Down syndrome -- improving memory, learning and communication.

9 Mar 2010

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

ISTA Pharmaceuticals, Inc., today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).

8 Mar 2010

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.

8 Mar 2010

FDA approves Taro Pharmaceutical Industries' Fluorouracil Topical Cream ANDA

Taro Pharmaceutical Industries Ltd. today reported that it received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Fluorouracil Topical Cream USP, 5%.

8 Mar 2010

BioSpecifics Technologies' XIAFLEX now available to Dupuytren's contracture patients in the U.S.

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX™ is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture patients with a palpable cord. Dupuytren's contracture is a debilitating disease resulting from excessive collagen deposition that causes contractures of the fingers.

8 Mar 2010

Rcadia Medical Imaging receives CE Mark for COR Analyzer System

Rcadia Medical Imaging today announced that it has received a CE Mark for the COR Analyzer® System, its proprietary software that helps identify patients with significant CAD (Coronary Artery Disease) by a fully automatic analysis of coronary CT angiography (cCTA) studies. The CE Mark allows the company to market the system in the European Union and other countries that accept the CE Mark registration. The COR Analyzer is marketed in the U.S. under 510(k) clearance and Rcadia was named 2009 Best New Radiology Vendor by AuntMinnie.com.

8 Mar 2010

Positive interim results from NxStage Medical's FREEDOM study in RLS

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today announced the latest interim results from its ongoing FREEDOM study, which show the significant improvement of overall sleep quality and marked improvement in Restless Legs Syndrome (RLS) experienced by patients after four months of daily home hemodialysis therapy with the NxStage System One™.

8 Mar 2010

Moderating treatment response in depression: Role of personality factors

A study published in the current issue of Psychotherapy and Psychosomatics addresses the role of personality factors in moderating treatment response in depression.

8 Mar 2010

Medical Condition News

Viatronix V3D-Colon software used for the President's colon cancer screening exam

Black and Hispanic Medicare beneficiaries with heart failure less likely to receive hospice care

Some anti-depressant drugs associated with increased chance of developing cataracts: Study

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

Well-characterized molecular alterations of sarcomas make them ideal models for developing new therapies

Study suggests early warning signs for autism spectrum disorders within families

Weight and risk for diabetes decrease for people in communities where fast food prices increase: Study

Obesity - Body's effort to protect organs from lipids' toxic effects

Study finds sizeable position for Actemra in rheumatoid arthritis treatment paradigm

New program specifically tailored to teens could help them manage and avoid asthma

RDS launches international outreach program on cognitive impairment in Down syndrome patients

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

FDA approves Taro Pharmaceutical Industries' Fluorouracil Topical Cream ANDA

BioSpecifics Technologies' XIAFLEX now available to Dupuytren's contracture patients in the U.S.

Rcadia Medical Imaging receives CE Mark for COR Analyzer System

Positive interim results from NxStage Medical's FREEDOM study in RLS

Moderating treatment response in depression: Role of personality factors

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Latest News